Sana Biotechnology (NASDAQ:SANA) Earns Buy Rating from Analysts at Jefferies Financial Group

Analysts at Jefferies Financial Group assumed coverage on shares of Sana Biotechnology (NASDAQ:SANA - Get Free Report) in a report released on Friday, Marketbeat.com reports. The brokerage set a "buy" rating and a $7.00 price target on the stock. Jefferies Financial Group's price target would suggest a potential upside of 138.91% from the stock's previous close.

SANA has been the topic of a number of other research reports. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright raised their price target on Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $12.25.

Sana Biotechnology Stock Performance

SANA traded up $0.28 during midday trading on Friday, hitting $2.93. The stock had a trading volume of 2,989,692 shares, compared to its average volume of 2,977,744. Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $10.50. The business has a fifty day moving average of $3.03 and a 200 day moving average of $3.27. The company has a market cap of $654.18 million, a P/E ratio of -2.09 and a beta of 1.63.

Remove Ads

Insider Activity at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the firm's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now directly owns 4,541,511 shares of the company's stock, valued at approximately $29,474,406.39. This trade represents a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 31.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC lifted its position in Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company's stock valued at $131,494,000 after buying an additional 4,438,949 shares during the period. Boxer Capital Management LLC bought a new stake in Sana Biotechnology during the fourth quarter worth about $2,518,000. Corient Private Wealth LLC grew its holdings in Sana Biotechnology by 161.7% in the fourth quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company's stock worth $1,928,000 after purchasing an additional 730,699 shares during the period. Millennium Management LLC increased its stake in shares of Sana Biotechnology by 604.8% during the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after purchasing an additional 625,481 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Sana Biotechnology by 44.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock valued at $2,538,000 after purchasing an additional 478,596 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.